Kenney Richard T, Edelman Robert
Clinical Development, Iomai Corporation, Gaithersburg, Maryland 20878, USA.
Expert Rev Vaccines. 2003 Apr;2(2):167-88. doi: 10.1586/14760584.2.2.167.
Although there are only four adjuvants used in licensed vaccines for humans, a wealth of information on novel vaccine adjuvants has become available in both animal models and clinical studies over the past decade. Many vaccine candidates require immunopotentiation to achieve a satisfactory immune response, which is driving the search for new and safer approaches. In this review, we take a brief look at what is known of the mechanisms of action, consider some of the elements of product development, then survey several of the classes of adjuvants within the context of human trials.
尽管在已获许可的人类疫苗中仅使用了四种佐剂,但在过去十年中,动物模型和临床研究都已提供了大量关于新型疫苗佐剂的信息。许多候选疫苗需要免疫增强才能产生令人满意的免疫反应,这推动了对更新、更安全方法的探索。在本综述中,我们简要了解一下已知的作用机制,考虑产品开发的一些要素,然后在人体试验的背景下审视几类佐剂。